Article
Nanoscience & Nanotechnology
Busra Cetin Ersen, Beyza Goncu, Aydan Dag, Gokcen Birlik Demirel
Summary: In this study, targeted and multimodal therapeutic hybrid nanocarriers were fabricated for breast cancer treatments. The carrier consists of synthesized gold nanorods coated with doxorubicin conjugated glycopeptide polymer. A photosensitizer molecule was loaded into the particles for photodynamic therapy, and antisense oligonucleotides were integrated to prevent apoptotic resistance. The biocompatibility and therapeutic efficacy of these nanoparticles were evaluated on human normal skin fibroblast and breast cancer cell lines.
ACS APPLIED MATERIALS & INTERFACES
(2023)
Article
Materials Science, Biomaterials
Yuqian Fu, Tingjie Bai, Panpan Xue, Qi Chen, Weili Deng, Shuangqian Yan, Xuemei Zeng
Summary: This study discovered that mannose can reverse tumor hypoxia and suppress the expression of heat shock protein by inhibiting ATP generation. The use of imLipo nanoparticles in both in vitro and in vivo experiments showed significant therapeutic efficacy for tumor treatment. The study suggests that glycolysis inhibition can overcome the challenges of phototherapy.
JOURNAL OF MATERIALS CHEMISTRY B
(2023)
Article
Medicine, Research & Experimental
Elena Lopez-Camacho, Lucia Trilla-Fuertes, Angelo Gamez-Pozo, Irene Dapia, Rocio Lopez-Vacas, Andrea Zapater-Moros, Maria Isabel Lumbreras-Herrera, Pedro Arias, Pilar Zamora, Juan Angel Fresno Vara, Enrique Espinosa
Summary: The combination of antimetabolic drugs with chemotherapy drugs showed synergistic effects on triple-negative breast cancer cells, leading to potential therapeutic strategies that reduce chemotherapy drug doses or enhance their efficacy.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Engineering, Biomedical
Lu Lu, Genhua Liu, Chuanchuan Lin, Ke Li, Tingting He, Jixi Zhang, Zhong Luo, Kaiyong Cai
Summary: The study introduces a novel nanocarrier for breast cancer treatment that targets both tumors and mitochondria, demonstrating great potential in enhancing the efficacy of cancer therapy.
ADVANCED HEALTHCARE MATERIALS
(2021)
Article
Multidisciplinary Sciences
Dario Zimmerli, Chiara S. Brambillasca, Francien Talens, Jinhyuk Bhin, Renske Linstra, Lou Romanens, Arkajyoti Bhattacharya, Stacey E. P. Joosten, Ana Moises Da Silva, Nuno Padrao, Max D. Wellenstein, Kelly Kersten, Mart de Boo, Maurits Roorda, Linda Henneman, Roebi de Bruijn, Stefano Annunziato, Eline van der Burg, Anne Paulien Drenth, Catrin Lutz, Theresa Endres, Marieke van de Ven, Martin Eilers, Lodewyk Wessels, Karin E. de Visser, Wilbert Zwart, Rudolf S. N. Fehrmann, Marcel A. T. M. van Vugt, Jos Jonkers
Summary: MYC plays a crucial role in suppressing anti-tumour immunity in triple-negative breast cancer by directly regulating the transcription of interferon signalling genes. MYC overexpression decreases lymphocyte infiltration in tumors and prevents the recruitment and activation of immune cells. These findings reveal the mechanisms by which MYC overexpression leads to poor immunogenicity in triple-negative breast cancer.
NATURE COMMUNICATIONS
(2022)
Review
Biochemistry & Molecular Biology
Linlin Lu, Zihe Niu, Zhujun Chao, Cuiping Fu, Kai Chen, Yaqin Shi
Summary: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer, and standard treatment options are limited. Antibody-drug conjugates (ADCs) have shown promise in clinical studies, but resistance is a challenge. Combining ADCs with other treatment strategies may provide a more effective approach.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2023)
Article
Chemistry, Multidisciplinary
Shiyan Dong, Ye Bi, Xiangshi Sun, Yarong Zhao, Rongze Sun, Fei Hao, Yating Sun, Yifan Wang, Xuefeng Li, Weiye Deng, Xuan Liu, JongHoon Ha, Lirong Teng, Ping Gong, Jing Xie, Betty Y. S. Kim, Zhaogang Yang, Wen Jiang, Lesheng Teng
Summary: This study describes a TNBC-specific targeted liposomal formulation that effectively targets TNBC tumor cells through hyaluronic acid modification and has synergistic effects on inhibiting tumor cell proliferation and metastasis.
Review
Oncology
Liying Li, Fan Zhang, Zhenyu Liu, Zhimin Fan
Summary: For decades, efforts have been made to develop targeted drugs for triple-negative breast cancer (TNBC), and immunotherapy has emerged as a promising approach. However, there are still gaps to be addressed. This review will analyze current immunotherapy strategies in TNBC, summarize the clinical trials landscape, and discuss future developments.
Article
Cell Biology
Fan Yang, Yi Xiao, Jia-Han Ding, Xi Jin, Ding Ma, Da-Qian Li, Jin-Xiu Shi, Wei Huang, Yi-Pin Wang, Yi-Zhou Jiang, Zhi-Ming Shao
Summary: By integrating multiomics data, this study revealed the ferroptosis landscape of TNBC and proposed an innovative immunotherapy combination strategy for refractory LAR tumors.
Article
Oncology
Nanda Kumar Yellapu, Thuc Ly, Mihaela E. Sardiu, Dong Pei, Danny R. Welch, Jeffery A. Thompson, Devin C. Koestler
Summary: The combination of JQ1 and GSK2801 synergistically inhibits proliferation and results in selective gene regulation in TNBC cell lines. Functional enrichment analysis identified several metabolic pathways enriched with differentially expressed genes when the drugs were co-administered. Molecular modeling studies also predicted the binding of the drugs with specific proteins, suggesting another mechanism for their effects on metabolism and proliferation.
Article
Nanoscience & Nanotechnology
Liyan Ming, Liang Song, Jixuan Xu, Ruoping Wang, Junpeng Shi, Min Chen, Yun Zhang
Summary: This study developed a smart manganese dioxide-based lanthanide nanoprobe therapeutic nanoplatform for tumor imaging and precise gene therapy in TNBC, combined with chemodynamic therapy. The nanoplatform exhibited high siRNA delivery efficiency and GSH-responsive precise siRNA releasing ability, with enhanced CDT effect due to GSH depletion, showing excellent NIR-II precise tumor imaging therapy.
ACS APPLIED MATERIALS & INTERFACES
(2021)
Article
Biotechnology & Applied Microbiology
Yuxia Tang, Siqi Wang, Yang Li, Chen Yuan, Jie Zhang, Ziqing Xu, Yongzhi Hu, Haibin Shi, Shouju Wang
Summary: In this study, molybdenum disulfide (MoS2) was used to deliver anti-PD-L1 antibody (aPDL1) and V9302 simultaneously to enhance the anti-tumor immune response in triple-negative breast cancer (TNBC) cells. The results showed that the combination of MoS2-aPDL1-V9302 effectively inhibited tumor growth and increased the proportion of activated T cells in the tumor microenvironment.
JOURNAL OF NANOBIOTECHNOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Yiyang Cong, Bo Sun, Jianlun Hu, Xiaoyang Li, Yanan Wang, Jingyi Zhang, Dongzhi Yang, Weifei Lu, Zhi Ding, Xiaofeng Wang, Hao Hong
Summary: This study developed a metal-organic framework nanoplatform that can produce carbon monoxide in a controllable manner and adjust tumor microenvironment during cancer therapy, providing a new therapeutic strategy.
JOURNAL OF NANOBIOTECHNOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Chongzhi Wu, Fu Zhang, Bowen Li, Zhiyao Li, Xin Xie, Yong Huang, Zhuo Yao, Yuan Chen, Yuan Ping, Weidong Pan
Summary: A new strategy for eradicating triple-negative breast cancer stem cells (TNBCSCs) is reported using a disulfide-mediated self-assembly nano-prodrug that co-delivers ferroptosis drug, differentiation-inducing agent, and chemotherapeutics for simultaneous treatment of TNBCSCs and TNBC.
Article
Immunology
Jianquan Yang, Wen Guo, Rong Huang, Jiaojiao Bian, Siqi Zhang, Ting Wei, Chuanshi He, Ziyue Hu, Juan Li, Chunyang Zhou, Man Lu
Summary: Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer with limited treatment options and poor prognosis. This study developed albumin-based nanospheres loaded with a photosensitizer and cGAS-STING agonists, which showed effectiveness in inducing pyroptosis, a form of immunogenic cell death, and activating the cGAS-STING signaling pathway. In vivo experiments demonstrated that this novel strategy inhibited tumor growth and enhanced the efficacy of anti-PD-L1 antibody treatment in TNBC.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Siqing Fu, Shuyang Yao, Yuan Yuan, Rebecca A. Previs, Anthony D. Elias, Richard D. Carvajal, Thomas J. George, Ying Yuan, Lihou Yu, Shannon N. Westin, Yan Xing, Ecaterina E. Dumbrava, Daniel D. Karp, Sarina A. Piha-Paul, Apostolia M. Tsimberidou, Jordi Rodon Ahnert, Naoko Takebe, Karen Lu, Khandan Keyomarsi, Funda Meric-Bernstam
Summary: This study aimed to evaluate the antitumor activity of adavosertib in patients with CCNE1-amplified, advanced refractory solid tumors. The results showed that adavosertib demonstrated a manageable toxicity profile and promising clinical activity in patients with CCNE1-amplified refractory solid tumors.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Colt A. Egelston, Weihua Guo, Susan E. Yost, Xuan Ge, Jin Sun Lee, Paul H. Frankel, Yujie Cui, Christopher Ruel, Daniel Schmolze, Mireya Murga, Aileen Tang, Norma Martinez, Misagh Karimi, George Somlo, Peter P. Lee, James R. Waisman, Yuan Yuan
Summary: This study evaluated the efficacy of pembrolizumab plus doxorubicin in patients with metastatic triple-negative breast cancer (mTNBC). The overall response rate was 67% and the clinical benefit rate was 56%. Immune correlates showed increased frequencies of T cells, indicating a robust T cell response with this combination treatment.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Oncology
Jennifer K. Litton, J. Thaddeus Beck, Jason M. Jones, Jay Andersen, Joanne L. Blum, Lida A. Mina, Raymond Brig, Michael Danso, Yuan Yuan, Antonello Abbattista, Kay Noonan, Alexander Niyazov, Jayeta Chakrabarti, Akos Czibere, William F. Symmans, Melinda L. Telli
Summary: This study evaluates the efficacy and safety of neoadjuvant talazoparib in patients with germline BRCA1/2-mutated early-stage TNBC. The results show that talazoparib monotherapy is active in these patients, although the pCR rates did not meet the prespecified threshold. Talazoparib was generally well tolerated.
Article
Oncology
Michael Rainone, Saro Kasparian, Tina Nguyen, Neel Talwar, Yuan Yuan, Matthew Mei, Joanne E. Mortimer, James R. Waisman, Niki Patel, Vinod Pullarkat
Summary: The efficacy of thrombopoietin receptor agonists (TPO-RA) in improving platelet counts due to HER2-targeted antibody-drug conjugate therapy remains unknown. This article reports a case series in which TPO-RA were successfully used to treat thrombocytopenia associated with trastuzumab emtansine and trastuzumab deruxtecan therapy in breast cancer patients. All 6 patients were able to resume therapy with TPO-RA support.
Article
Medicine, General & Internal
Dana Mahin, Sayeh Moazami Lavasani, Leon Cristobal, Niki Tank Patel, Mina Sedrak, Daphne Stewart, James Waisman, Yuan Yuan, Wai Yu, Raynald Samoa, Nora Ruel, Susan E. E. Yost, Hayley Lee, Sung Hee Kil, Joanne E. E. Mortimer
Summary: Glucocorticoids administered with chemotherapy cause hyperglycemia in breast cancer patients. A retrospective study analyzed random blood glucose levels in early-stage breast cancer patients who received dexamethasone prior to chemotherapy. The incidence of steroid-induced hyperglycemia (SIH) was 67%, and it was highest in patients with glucose levels of >200 mg/dL. Non-Hispanic White patients had a higher risk of developing SIH, but over 90% of the patients had transient hyperglycemia.
JOURNAL OF CLINICAL MEDICINE
(2023)
Meeting Abstract
Oncology
Erika P. Hamilton, Ololade Dosunmu, Mythili Shastry, Lindsey Finney, Dalila B. Sellami, David W. Sternberg, Vance Wright-Browne, Deborah Toppmeyer, William R. Gwin, J. Thaddeus Thaddeus, Jennifer L. Cultrera, Nusayba Ali Bagegni, Katia Khoury, Arielle Lutterman Heeke, Yuan Yuan
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Jamie Green Rand, Dave Yamauchi, Shyambabu Chaurasiya, Jianying Zhang, Raju Pillai, Colt Egelston, Jonathan Kessler, Badri Modi, Leslie Chong, Amanda Seiz, Giovanni Selvaggi, Nick Ede, Mireya Murga, Norma Martinez, Wichanee Borisuthirattana, Hans Meisen, Susan Yost, James Waisman, Daphne Stewart, Joanne Mortimer, Yuman Fong, Yuan Yuan
Meeting Abstract
Oncology
Yara Abdou, E. Claire Dees, Joanne Mortimer, Naoto Ueno, Melissa Johnson, Richard Maziarz, Jennifer Specht, Yuan Yuan, Paula Puhlman, Mathew Angelos, Saar Gill, Amy Ronczka, Thomas Condamine, Daniel J. Cushing, Michael Klichinsky, Debora Barton, Ramona F. Swaby, Kim Reiss Binder
Meeting Abstract
Oncology
Yuan Yuan, Colt A. Egelston, Weihua Guo, Susan E. Yost, Paul H. Frankel, Christopher Ruel, Mireya Murga, Aileen Tang, Norma Martinez, Daniel Schmolze, Daphne Stewart, James Waisman, Kelly Yap, Joanne Mortimer, Niki Tank
Meeting Abstract
Oncology
Yuan Yuan, Jamie G. Rand, Jianying Zhang, Jonathan Kessler, Badri Modi, Raju Pillai, Colt A. Egelston, Shyambabu Chaurasiya, Mireya Murga, Aileen Tang, Norma Martinez, Hans Meisen, Dave Yamauchi, Susan E. Yost, Leslie Chong, Amanda Seiz, Bonnie Nixon, Nick Ede, James Waisman, Daphne Stewart, Mina S. Sedrak, Yuman Fong
Meeting Abstract
Oncology
Colt A. Egelston, Weihua Guo, Susan E. Yost, Xuan Ge, Jin Sun Lee, Paul H. Frankel, Yujie Cui, Christopher Ruel, Daniel Schmolze, Mireya Murga, Aileen Tang, Norma Martinez, Misagh Karimi, George Somlo, Peter Lee, James Waisman, Yuan Yuan
Meeting Abstract
Oncology
Francesca Menghi, Kalyan Banda, Pooja Kumar, Robert Straub, Lacey E. Dobrolecki, Isabel Rodriguez, Susan E. Yost, Harshpreet Chandok, Marc Radke, George Somlo, Yuan Yuan, Michael T. Lewis, Elizabeth Swisher, Edison Liu
Article
Oncology
Yuan Yuan, Susan E. Yost, Yujie Cui, Christopher Ruel, Mireya Murga, Aileen Tang, Norma Martinez, Daniel Schmolze, James Waisman, Niki Patel, Lalit Vora, Lusine Tumyan, Mari Bozoghlanian, Daphne Stewart, Paul H. Frankel
Summary: This trial evaluated the safety and efficacy of ipatasertib in combination with different chemotherapy regimens for metastatic triple-negative breast cancer (mTNBC). The results showed that continuous dosing of ipatasertib with chemotherapy was safe and well-tolerated, and the overall response rates and progression-free survival varied among the different treatment arms. Further study is needed to better understand the role of AKT inhibition in the treatment of TNBCs.